ejpmr, 2023,10(10), 306-314

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Research Article

ISSN 2394-3211

EJPMR

METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTITATIVE ESTIMATION OF TRAMETINIB IN API FORM AND MARKETED TABLET DOSAGE FORM BY RP-HPLC

A. Myna[1]*, M. Tandrima[2], A. Yasodha[3] and K. Sujatha[4]

[1]Pharmaceutical Analysis, Dhanvanthri College of Pharmaceutical Sciences, Thirumala Hills, Centre City, Appannapally, Mahabubnagar, Telangana 509001.

[2]Assosiate Professor, Pharmaceutical Chemistry, Dhanvanthri College of Pharmaceutical Sciences, Thirumala Hills, Centre City, Appannapally, Mahabubnagar, Telangana 509001.

[3]Principal, Professor, Pharmaceutical Analysis, Dhanvanthri College of Pharmaceutical Sciences, Thirumala Hills, Centre City, Appannapally, Mahabubnagar, Telangana 509001.

[4]Assistant Professor, Pharmaceutical Analysis, Dhanvanthri College of Pharmaceutical Sciences, Thirumala Hills, Centre City, Appannapally, Mahabubnagar, Telangana 509001.

***Corresponding Author: A. Myna**
[1]Pharmaceutical Analysis, Dhanvanthri College of Pharmaceutical Sciences, Thirumala Hills, Centre City, Appannapally, Mahabubnagar, Telangana 509001.

Article Received on 07/08/2023 **Article Revised on 27/08/2023** **Article Accepted on 17/09/2023**

ABSTRACT

A Simple, rapid, accurate, precise, robust and efficient and simple RP-HPLC method has been developed and validated for the determination of Trametinib in bulk and was applied on marketed Trametinib products. The mobile phase used for the chromatographic runs consisted of Acetonitrile and Phosphate buffer (0.01M, pH-3.2) in the ratio of 30:70% v/v. The separation was achieved on a Symmetry C_{18} ODS (4.6mm × 250mm) 5µm particle size column using isocratic mode. Drug peak were well separated and were detected by a UV detector at 246 nm. The method was linear at the concentration range 6–14 µg/ml for Trametinib. The method has been validated according to ICH guidelines with respect to system suitability, specificity, precision, accuracy and robustness. Trametinib limit of detection (LOD) and limit of quantification (LOQ) were 0.487µg/ml and 1.477µg/ml respectively.

KEYWORDS: Trametinib, RP-HPLC, Accuracy, Precision, Robustness, ICH Guidelines.

INTRODUCTION

Trametinib is an orally bioavailable inhibitor of mitogen-activated protein kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, Trametinib[1] specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth. Trametinib is an anticancer agent which causes apoptosis (or programmed cell death) and inhibits cell proliferation, which are both important in the treatment of malignancies. Trametinib[2] is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. Trametinib helps with melanoma with the BRAF V600E or V600K as the mutation results in the constitutive activation of the BRAF pathway which includes MEK1 and MEK2. Trametinib[3] is used alone or in combination with Dabrafenib (Tafinlar) to treat a certain types of melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. The IUPAC name of Trametinib is N-[3-[3-cyclo propyl-5-(2-fluoro-4-iodo anilino)-6, 8-dimethyl-2, 4, 7-trioxopyrido [4, 3-d] pyrimidin-1-yl] phenyl] acetamide. The Chemical Structure of Trametinib is shown in fig-1.



Fig. 1: Chemical structure of trametinib.

MATERIALS AND METHODS

Materials and Instruments:

The following are the list of instruments/Equipments, chemicals/reagents and standards to perform the HPLC Analysis[4] of the drug Trametinib.

Equipments:

Table 1: List of equipments.

S. No.	Instruments/Equipments/Apparatus
1.	HPLC WATERS with Empower2 Software with Isocratic with UV-Visible Detector.
2.	T60-LABINDIA UV – Vis spectrophotometer
3.	High Precision Electronic Balance
4.	Ultra Sonicator (Wensar wuc-2L)
5.	Thermal Oven
6.	Symmetry C_{18} Column, 250 mm x 4.6 mm and 5µm particle size
7.	P^H Analyser (ELICO)

Chemicals and Reagents:

Table 2: List of chemicals used.

S. No.	Name	Grade	Manufacturer/Supplier
1.	HPLC grade water	HPLC	Sd fine-Chem ltd; Mumbai
2.	Methanol	HPLC	Loba Chem; Mumbai.
3.	Ethanol	A.R.	Sd fine-Chem ltd; Mumbai
4.	Acetonitrile	HPLC	Loba Chem; Mumbai.
5.	DMSO	A.R.	Sd fine-Chem ltd; Mumbai
6.	DMF	A.R.	Sd fine-Chem ltd; Mumbai

Working standard: Working Standard of Trametinib: 10ppm

Method development:

HPLC Instrumentation & Conditions: The HPLC system[5] employed was **HPLC WATERS** with Empower2 Software with Isocratic with UV-Visible Detector.

Standard Preparation for UV-Spectrophotometer analysis:

The standard stock solutions – 10 mg of Trametinib standard was transferred into 10 ml volumetric flask, dissolved & make up to volume with Methanol. Further dilutions were done by transferring 1 ml of the above solution into a 10ml volumetric flask and make up to volume with methanol to get 10ppm concentration.

It scanned in the UV spectrum[6] in the range of 200 to 400nm. This has been performed to know the maxima of Trametinib, so that the same wave number can be utilized in HPLC UV detector for estimating the Trametinib.

Wavelength detection:

The detection wavelength was selected by dissolving the drug in mobile phase[7] to get a concentration of 10µg/ml for individual and mixed standards. The resulting solution was scanned in U.V range from 200-400nm. The UV spectrum of Trametinib was obtained and the Trametinib showed absorbance's maxima at 246nm. The UV spectra of drug are follows:



Fig. 2: UV Spectrum of Trametinib (246nm).

Observation: While scanning the Trametinib solution we observed the maxima at 246nm. The UV spectrum has been recorded on T60-LAB INDIA make UV – Vis spectrophotometer model UV-2450.

Selection of chromatographic methods:
The proper selection depends upon the nature of the sample, (ionic or ion stable or neutral molecule) its molecular weight and stability.[8] The drugs selected are polar, ionic and hence reversed phase chromatography was selected.

Optimization of column:
The method was performed with various columns like Hypersil C_{18} column, X- bridge column and X-terra (4.6 ×150mm, 5µm particle size), Symmetry C18 ODS (4.6mm×250mm) 5µm particle size Column[9] was found to be ideal as it gave good peak shape and resolution at 1ml/min flow.

Mobile phase optimization:
Initially the mobile phase tried was Water: Methanol and Water: Acetonitrile and Methanol with TEA Buffer with varying proportions. Finally, the mobile phase was optimized to Acetonitrile: Phosphate buffer (0.01M, pH-3.2) in the ratio of 30:70 respectively.

Estimation of trametinib in Bulk and Pharmaceutical dosage form:
Procedure
Preparation of mobile phase:
Accurately measured 300 ml (300%) of HPLC Grade Acetonitrile and 700 ml of Phosphate buffer (70%) were mixed and degassed[10] in a digital ultra sonicater for 15 minutes and then filtered through 0.45 µ filter under vacuum filter.

Preparation of 0.01M Potassium dihydrogen orthophosphate buffer solution:
About 1.36086grams of Potassium dihydrogen orthophosphate was weighed and transferred into a 1000ml beaker, dissolved and diluted to 1000ml with HPLC Grade water. The pH was adjusted to 3.20 with diluted orthophosphoric acid.

Diluent preparation:
Accurately measured 300 ml (300%) of HPLC Grade Acetonitrile and 700 ml of Phosphate buffer (70%) were mixed and degassed in a digital ultra sonicater for 15 minutes and then filtered through 0.45 µ filter under vacuum filter.

Assay
Preparation of the trametinib standard solution:
Preparation of standard solution: (Trametinib)
Accurately weigh and transfer 10 mg of Trametinib, working standard into a 10ml of clean dry volumetric flasks add about 7ml of diluent and sonicate to dissolve and removal of air completely and make volume up to the mark with the diluent.

Further pipette 0.1ml of Trametinib from stock solution in to a 10ml volumetric flask and dilute up to the mark with diluent.[11]

Procedure:
Inject the samples by changing the chromatographic conditions and record the chromatograms, note the conditions of proper peak elution for performing validation parameters as per ICH guidelines.[12,13,18]

Preparation of Sample Solution:
Take average weight of Tablet and crush in a mortar by using pestle and taken weight 10 mg equivalent weight of Trametinib sample into a 10ml clean dry volumetric flask and add about 7ml of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Procedure:
Further pipette 0.1ml of Trametinib from above stock solution into a 10ml volumetric flask and dilute up to the mark with diluent.

Inject the three replicate injections of standard and sample solutions[14] and calculate the assay by using formula:

$$\%ASSAY = \frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

Analytical method validation
Validation[15] is a process of establishing documented evidence which provide a high degree of assurance that specific activity will consistently produce a desired result or product meeting its predetermined specification and quality characteristics.

A. System suitability
System suitability is the evaluation of the components of an analytical system to show that the performance of a system meets the standards required by a method. A system suitability evaluation usually contains its own set of parameters. For chromatographic assays, these may include tailing factor, resolution, precision, capacity factor time and theoretical plates.

B. Accuracy:
For preparation of 50% standard stock solution:
Further pipette 0.05ml of Trametinib from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

For preparation of 100% Standard stock solution:
Further pipette 0.1ml of Trametinib from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

For preparation of 150% standard stock solution:
Further pipette 0.15 ml of Trametinib from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Procedure:
Inject the Three replicate injections of individual concentrations (50%, 100%, 150%) were made under the optimized conditions. Recorded the chromatograms and measured the peak responses. Calculate the Amount found and Amount added for Trametinib and calculate the individual recovery and mean recovery values.

Acceptance criteria:
The %RSD for each level should not be more than 2 .

C. Precision:
Repeatability
Preparation of trametinib for precision:
Further pipette 0.1 ml of Trametinib from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent

The standard solution was injected for five times and measured the area for all five injections in HPLC. The %RSD for the area of five replicate injections was found to be within the specified limits.

D. Ruggedness
To evaluate the intermediate precision of the method, Precision was performed on different days by maintaining same conditions.

Procedure:
Day 1:
The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Day 2:
The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

The % RSD for the area of five standard injections results should be not more than 2%.

E. Linearity:
Preparation of Level – I (6µg/ml of Trametinib):
Further pipette 0.06 ml of Trametinib from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Preparation of Level – II (8µg/ml of Trametinib):
Further pipette 0.08 ml of Trametinib from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Preparation of Level – III (10µg/ml of Trametinib):
Further pipette 0.1ml of Trametinib from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Preparation of Level – IV (12µg/ml of Trametinib):
Further pipette 0.12ml of Trametinib from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Preparation of Level – V (14µg/ml of Trametinib):
Further pipette 0.14ml of Trametinib from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Procedure:
Inject each level into the chromatographic system and measure the peak area. Plot a graph of peak area versus concentration (on X-axis concentration and on Y-axis Peak area) and calculate the correlation coefficient.

Acceptance Criteria: Correlation coefficient should be not less than 0.999.

F. Limit of detection:
The detection limit is determined by the analysis of samples with known concentration of analyte and by establishing that minimum level at which the analyte can reliably detected.

G. Limit of quantitation
The quantification limit is generally determined by the analysis of sample with known concentrations of analyte and by establishing the minimum level at which the analyte can be quantified with acceptable accuracy and precision.

H. Robustness:
The analysis was performed in different conditions to find the variability of test results. The following conditions are checked for variation of results. .

Effect of variation of flow rate:
The sample was analyzed at 0.9 ml/min and 1.1 ml/min instead of 1ml/min, remaining conditions are same. 20µl of the above sample was injected and chromatograms were recorded.

Effect of variation of mobile phase organic composition:
The sample was analyzed by variation of mobile phase i.e. Acetonitrile: Phosphate Buffer was taken in the ratio and 70:30, 75:25 instead of 65:35, remaining conditions are same. 20µl of the above sample was injected and chromatograms were recorded.

Forced degradation studies:
The specificity of the method can be demonstrated by applying stress conditions using acid, alkaline, peroxide, thermal, UV, water degradations. The sample was exposed to these conditions the main peak of the drug was studied for peak purity that indicating the method effectively separated the degradation products from the pure active ingredient.

RESULTS AND DISCUSSION
Method development:

Optimized chromatographic conditions:
Mobile phase: Acetonitrile: Phosphate buffer (0.01M, pH-3.2) (30:70v/v)
Column: Symmetry C18 ODS (4.6mm×250mm) 5µm particle size
Flow rate: 1 ml/min
Wavelength: 246 nm
Column temp: Ambient
Injection Volume: 20 µl
Run time: 10 minutes



Fig. 3: Optimized chromatogram.

Preparation of 0.01M Potassium dihydrogen orthophosphate buffer solution:
About 1.36086grams of Potassium dihydrogen orthophosphate was weighed and transferred into a 1000ml beaker, dissolved and diluted to 1000ml with HPLC Grade water. The pH was adjusted to 3.20 with diluted orthophosphoric acid.

Preparation of standard solution:
10 mg of Trametinib working standard was accurately weighed and transferred into a 10 ml clean dry volumetric flask. Add about 7 ml of diluents and sonicate to dissolve it completely and volume was made up to the mark with the same solvent which gave stock solution of 1000 ppm.

Further pipette 1 ml of the above stock solution into a 10 ml volumetric flask was diluted up to the mark with diluents (100 ppm solution).

Further 1 ml of prepared 100 ppm solution was pipetted into a 10 ml volumetric flask and was diluted up to the mark with diluents which gave 10 ppm Trametinib working standard solution. The solution was mixed well and filtered through 0.45µm filter.

Preparation of sample solution:
Twenty tablets were taken and the average weight was calculated as per the method prescribed in I.P. The weighed tablets were finally powdered and triturated well. A quantity of powder of Trametinib equivalent to 10mg were transferred to clean and dry 10 ml volumetric flask and 7 ml of HPLC grade methanol was added and the resulting solution was sonicated for 15 minutes. Make up the volume up to 10 ml with same solvent. Then 1 ml of the above solution was diluted to 10 ml with HPLC grade methanol. One ml (0.1 ml) of the prepared stock solution diluted to 10 ml and was filtered through membrane filter (0.45µm) and finally sonicated to degas.

Method validation
System suitability:
Table 3: Observation of system suitability parameters.

S. No.	Parameter	Trametinib
1	Retention Time (min)	5.453
2	Theoretical Plates	6967
3	Tailing factor	1.12
4	Peak Area (AUC)	647856

Specificity
The ICH documents define specificity[16] as the ability to assess unequivocally the analyte in the presence of components that may be expected to be present, such as impurities, degradation products, and matrix components. Analytical method was tested for specificity to measure accurately quantitates Trametinib in drug product.

$$\%ASSAY = \frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

The % purity of Trametinib in present in the marketed pharmaceutical dosage form was found to be 99.85%.

Linearity

Chromatographic data for linearity study:

Table 4: Chromatographic data for linearity study of trametinib.

Concentration µg/ml	Average Peak Area
6	468784
8	615798
10	768759
12	925748
14	1078765



Fig. 4: Calibration curve of trametinib.

Linearity plot:

The plot of Concentration (x) versus the Average Peak Area (y) data of Trametinib is a straight line.

Y = mx + c

Slope (m) = 76943

Intercept (c) = 1787

Correlation Coefficient (r) = 0.99

Validation criteria: The response linearity[17] is verified if the Correlation Coefficient is 0.99 or greater.

Conclusion: Correlation Coefficient (r) is 0.99, and the intercept is 76943. These values meet the validation criteria.

Precision:

The precision[18] of an analytical procedure expresses the closeness of agreement (degree of scatter) between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions.

Repeatability: Obtained Six (6) replicates of 100% accuracy solution as per experimental conditions. Recorded the peak areas and calculated % RSD.

Table 5: Results of repeatability for trametinib.

S. No.	Peak Name	Retention time	Area (µV*sec)	Height (µV)	USP Plate Count	USP Tailing
1	Trametinib	5.419	645784	83685	6825	1.05
2	Trametinib	5.405	642589	84932	6849	1.09
3	Trametinib	5.478	643658	85847	6845	1.08
4	Trametinib	5.466	648759	86295	6839	1.09
5	Trametinib	5.493	649657	86587	6895	1.07
6	Trametinib	5.466	647854	87853	6874	1.10
Mean			**646383.5**			
Std. Dev			**2853.319**			
%RSD			**0.441428**			

Intermediate Precision/Ruggedness:

Analyst 1:

Table 6: Results of intermediate precision for trametinib.

S. No.	Peak Name	RT	Area (µV*sec)	Height (µV)	USP Plate Count	USP Tailing
1	Trametinib	5.484	636854	84863	6758	1.09
2	Trametinib	5.493	637489	84759	6726	1.08
3	Trametinib	5.406	635762	84685	6749	1.09
4	Trametinib	5.419	636984	84697	6698	1.07
5	Trametinib	5.446	634856	84258	6728	1.08
6	Trametinib	5.452	639689	84753	6699	1.08
Mean			**636939**			
Std. Dev.			**1649.149**			
% RSD			**0.258918**			

Analyst 2:

Table 7: Results of intermediate precision analyst 2 for trametinib.

S. No.	Peak Name	RT	Area (µV*sec)	Height (µV)	USP Plate Count	USP Tailing
1	Trametinib	5.491	628985	85698	6985	1.09
2	Trametinib	5.482	624879	85479	6899	1.07
3	Trametinib	5.416	625846	85748	6928	1.06
4	Trametinib	5.482	623568	85647	6874	1.09
5	Trametinib	5.495	628985	85246	6984	1.07
6	Trametinib	5.427	628473	85924	6872	1.08
Mean			**626789.3**			
Std. Dev.			**2340.636**			
% RSD			**0.373433**			

Accuracy:

Accuracy at different concentrations (50%, 100%, and 150%) was prepared and the % recovery[19] was calculated.

Table 8: The accuracy results for trametinib.

%Concentration (at specification Level)	Area	Amount Added (ppm)	Amount Found (ppm)	% Recovery	Mean Recovery
50%	386559	5	5.00	100.000%	100.130%
100%	768536	10	9.965	99.650%	
150%	1164522	15	15.111	100.740%	

Limit of detection for trametinib

The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected[20] but not necessarily quantitated as an exact value.

LOD= 3.3 × σ / s

Where,

σ = Standard deviation of the response

S = Slope of the calibration curve

Result:

= 0.487µg/ml

Quantitation Limit

The quantitation limit[21] of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined.

LOQ = 10×σ/S

Where,

σ = Standard deviation of the response

S = Slope of the calibration curve

Result:

= 1.477µg/ml

Robustness

The robustness[22] was performed for the flow rate variations from 0.9 ml/min to 1.1ml/min and mobile phase ratio variation from more organic phase to less organic phase ratio for Trametinib. The method is robust only in less flow condition. The standard of Trametinib was injected by changing the conditions of chromatography.[23] There was no significant change in the parameters like resolution, tailing factor, asymmetric factor, and plate count.

Table 9: Results for robustness.

Parameter used for sample analysis	Peak Area	Retention Time	Theoretical plates	Tailing factor
Actual Flow rate of 1.0 mL/min	648759	5.484	6845	1.08
Less Flow rate of 0.9 mL/min	635248	5.599	6786	1.09
More Flow rate of 1.1 mL/min	659865	4.576	6528	1.05
Less organic phase	625986	7.415	6689	1.03
More organic phase	615869	3.827	6354	1.01

Forced degradation studies

The specificity of the method can be demonstrated by applying stress conditions[24-25] using acid, alkaline, peroxide, thermal, UV, water degradations. The sample was exposed to these conditions the main peak of the drug was studied for peak purity that indicating the method effectively separated the degradation products from the pure active ingredient.

Table 10: Results of forced degradation studies for trametinib.

S. No.	Stress Condition	Peak Area	% of Degraded Amount	% of Active Amount	Total % of Amount
1	Standard	648759	0	100%	100%
2	Acidic	539378.232	16.86	83.14	100%
3	Basic	603540.497	6.97	93.03	100%
4	Oxidative	545217.063	15.96	84.04	100%
5	Thermal	616450.801	4.98	95.02	100%
6	Photolytic	533344.773	17.79	82.21	100%
7	Water	625079.296	3.65	96.35	100%

SUMMARY AND CONCLUSION

The analytical method was developed by studying different parameters. First of all, maximum absorbance was found to be at 246nm and the peak purity was excellent. Injection volume was selected to be 20µl which gave a good peak area. The column used for study was Symmetry C18 ODS (4.6mm×250mm) 5µm particle size because it was giving good peak. Ambient temperature was found to be suitable for the nature of drug solution. The flow rate was fixed at 1.0ml/min because of good peak area and satisfactory retention time. Mobile phase is Acetonitrile: Phosphate buffer (0.01M, pH-3.2) (30:70 v/v) was fixed due to good symmetrical peak. So this mobile phase was used for the proposed study. Methanol was selected because of maximum extraction sonication time was fixed to be 10min at which all the drug particles were completely soluble and showed good recovery. Run time was selected to be 10min because analyze gave peak around 5.453min and also to reduce the total run time. The percent recovery was found to be 98.0-102 was linear and precise over the same range. Both system and method precision was found to be accurate and well within range. The analytical method was found linearity over the range of 6-14ppm of the Trametinib target concentration. The analytical passed both robustness and ruggedness tests. On both cases, relative standard deviation was well satisfactory.

BIBLIOGRAPHY

1. https://go.drugbank.com/drugs/DB08911
2. https://pubchem.ncbi.nlm.nih.gov/compound/Trametinib
3. https://en.wikipedia.org/wiki/Trametinib
4. Instrumental Analysis, Skoog, Fifth edition, 312-316.
5. Instrumental methods of chemical analysis, Gurdeep R. Chatwal, 2.116-2.122.
6. Elementary organic analysis, Principles and chemical applications, Y R Sharma, 12-14.
7. A textbook of pharmaceutical analysis, Kasturi A V, 3, 10: 169-81.
8. Willard-Hobart H, Merritt Jr Lynne L, Dean John A Instrumental Methods of Analysis. Von Nostrand, University of Michigan, 1974; 5.
9. Chatwal GR, Anand S Instrumental Methods of Chemical Analysis. Himalaya Publishing House, New Delhi, 2002; 5.
10. Davidson AG Ultraviolet-visible absorption Spectrophotometry. In Beckett AH, Stenlake JB, Practical Pharmaceutical chemistry. CBS Publishers and distributors, New Delhi, 2002; 4: 275-278.
11. Robert AN, Pharmaceutical process validation, publisher Marcel Dekker, Inc, 2003; 507-522.
12. Text on Validation of Analytical Procedures Q2A in; I.C.H. Harmonized Tripartite Guidelines, 1994.
13. Text on Validation of Analytical Procedures Q2B in; I.C.H. Harmonized Tripartite Guidelines, 1996.
14. Indian Pharmacopoeia published by the Indian Pharmacopeia commission Ghaziabad, 2014; 2191-2194.
15. USP NF, The Official Compendia of Standards, Asian edition, 2008; 2662-2663.

16. British Pharmacopeia amended by supplements, 2004; 4.1-4.8 inclusive: 2577.
17. Wegscheider, Validation of Analytical Methods, in: Accreditation and Quality Assurance in Analytical Chemistry, H. Guenzler, Springer (Ed.) Verlag and Berlin 1996.
18. Validation of Analytical Procedures: Text and Methodology, ICH Harmonized Tripartite Guideline. Q2 (R1), International Conference on Harmonization, Geneva, 2005, 1-13.
19. L.A. Woodward, Introduction to the Theory of Molecular Vibration and Vibrational Spectroscopy, Oxford University Press, London, 1972.
20. W.A. Guillory, Introduction to Molecular Structure and Spectroscopy, Allyn and Baccon Inc., Boston, 1977.
21. G. Herzberg, Infrared and Raman Spectra of Polyatomic Molecules, Van Nostrand, New York, 1964.
22. N.B. Colthup, L.H. Daly, S.E. Wiberely, Introduction to Infrared and Raman Spectroscopy, Academic press, New York, 1964.
23. G.F. Dyke, A.J. Floyd, M. Sainsbyrg, R.S. Theobald, Organic Spectroscopy: An Introduction, Longman Inc., New York, 1981.
24. D.N. Satyanarayana, Vibrational Spectroscopy Theory and Application, New Age International publishers, New Delhi, 2004.
25. R.E. Dpdd, Chemical Spectroscopy, Elsevier Publishing Company, New York, S.D. Ross, Inorganic Infrared and Raman spectra, Mc Graw-Hill, London, 1962; 1972: 10.
26. B. Ramakrishna, N. Sarat Babu and NVS Naidu*, Method Development and Validation of Rp-Hplc For Assay of Trametinib in Pharmaceutical Dosage Form, European Journal of Pharmaceutical and Medical Research, ejpmr, 2018; 5(3): 318-325.
27. Santhosh Illendula* and G. Mariya Therisa, Simultaneous Estimation of Latest Analytical Method Improvement and Validation of Dabrafenib and Trametinib By Means of High-Performance Liquid Chromatography, World Journal of Pharmacy and Pharmaceutical Sciences, 10, 3: 1978-2004.
28. L. Satyanarayana, S.V. Naidu, M. Narasimha Rao, Reddy Suma Latha, The Estimation of Nilotinib in Capsule dosage form by RP-HPLC, Asian Journal of Pharmaceutical Analysis, 2011; 1(4): 100-102.
29. Dara Varun Kumar1 and Kumaraswamy Gandla2, Method Development and Validation of Anticancer Drugs (Nilotinib and Gemcitabine) by RP-HPLC Method, World Journal of Pharmaceutical and Medical Research, wjpmr, 2021; 7(11): 150 – 160.
30. Ramana Reddy Gopireddy, Arthanareeswari Maruthapillai, A stability indicating method development and validation for separation of process related impurities and characterization of unknown impurities of tyrosine kinase inhibitor Nilotinib by RP-HPLC, NMR spectroscopy and ESI-MS, Materials today: Proceedings, 2021; 40, 1: S127-S138.
31. Azra Takhvar 1, Somaye Akbari 1, Effat Souri 1, Reza Ahmadkhaniha 2, Ali Morsali 3, Mohammad Reza Khoshayand 4, Mohsen Amini 1, Development and validation of RP-HPLC method for simultaneous quantification of the anticancer agents, Nilotinib and Sorafenib: Application in In-vitro analysis, Progress in Chemical and Biochemical Research, 2022; 5 (1): 44-52.